Bernard J. Escudier
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Renal cell carcinoma treatment
- Cancer Research top 0.02%
- Cancer Genomics and Diagnostics
Papers in
-
- Renal cell carcinoma treatment 390
- Cancer Research 109
- Cancer Genomics and Diagnostics 98
- Co-authors
- Camillo Porta (54 shared papers)Sylvie Négrier (58 shared papers)Brian I. Rini (56 shared papers)Alain Ravaud (59 shared papers)Stéphane Marie. Oudard (45 shared papers)Thomas E. Hutson (32 shared papers)Robert John Motzer (80 shared papers)Christine Chevreau (37 shared papers)
- Journals
- Annals of Oncology (100 papers)European Journal of Cancer (52 papers)European Urology (31 papers)Journal of Clinical Oncology (27 papers)Clinical Genitourinary Cancer (23 papers)
- Partner nations
- FranceUnited StatesItaly
In The Last Decade
Bernard J. Escudier
575 papers receiving 69.3k citations
Bernard J. Escudier's Hit Papers
Peers
Comparison fields: 5 of 171
- Pulmonary and Respiratory Medicine 36.0k
- Cancer Research 14.2k
- Oncology 21.4k
- Molecular Biology 26.0k
- Immunology 7.7k
Countries citing papers authored by Bernard J. Escudier
This map shows the geographic impact of Bernard J. Escudier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernard J. Escudier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernard J. Escudier more than expected).
Fields of papers citing papers by Bernard J. Escudier
This network shows the impact of papers produced by Bernard J. Escudier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernard J. Escudier. The network helps show where Bernard J. Escudier may publish in the future.
Co-authors
The 25 scholars most cited alongside Bernard J. Escudier, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 587 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2015 | 4815 |
| 2 | Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors Hit paper breakdown → | 2017 | 4482 |
| 3 | Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma Hit paper breakdown → | 2007 | 4078 |
| 4 | Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2018 | 3643 |
| 5 | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Hit paper breakdown → | 2008 | 2538 |
| 6 | Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2014 | 1960 |
| 7 | Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Hit paper breakdown → | 2007 | 1845 |
| 8 | Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Hit paper breakdown → | 2011 | 1544 |
| 9 | Renal cell carcinoma Hit paper breakdown → | 2009 | 1352 |
| 10 | Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2021 | 1323 |
| 11 | Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial Hit paper breakdown → | 2005 | 1122 |
| 12 | Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma Hit paper breakdown → | 2018 | 1011 |
| 13 | Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2015 | 1004 |
| 14 | Phase 3 trial of everolimus for metastatic renal cell carcinoma Hit paper breakdown → | 2010 | 983 |
| 15 | Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial Hit paper breakdown → | 2009 | 934 |
| 16 | Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2019 | 869 |
| 17 | Malignant effusions and immunogenic tumour-derived exosomes Hit paper breakdown → | 2002 | 839 |
| 18 | Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial Hit paper breakdown → | 2019 | 817 |
| 19 | CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner Hit paper breakdown → | 2005 | 795 |
| 20 | Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma Hit paper breakdown → | 1998 | 783 |
About Bernard J. Escudier
Bernard J. Escudier is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Molecular Biology and Immunology, having authored 587 papers that have together received 70.8k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (390 papers), Renal and related cancers (109 papers), Cancer Genomics and Diagnostics (98 papers), Cancer Immunotherapy and Biomarkers (55 papers), Economic and Financial Impacts of Cancer (31 papers), Immune Cell Function and Interaction (24 papers), Bladder and Urothelial Cancer Treatments (21 papers) and Pancreatic and Hepatic Oncology Research (21 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (36.0k citations), Cancer Research (14.2k citations), Oncology (21.4k citations), Molecular Biology (26.0k citations) and Immunology (7.7k citations). Bernard J. Escudier has collaborated with scholars based in France, United States and Italy. Frequent co-authors include Camillo Porta, Sylvie Négrier, Brian I. Rini, Alain Ravaud, Stéphane Marie. Oudard, Thomas E. Hutson, Robert John Motzer, Christine Chevreau, Cezary A. Szczylik and Sergio Bracarda. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, European Urology, Journal of Clinical Oncology and Clinical Genitourinary Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.